Nomograms as Predictive Tools for Prostate Cancer Patients Who Had Radical Prostatectomy

Saadettin Eskicorapci, Cenk Acar, Zafer Sinik, Zafer Aybek, Michael Kattanb

.

DOI: 10.4236/oju.2011.13009                

Abstract

Prostate cancer is the most common solid cancer for men in the developed countries. Radical prostatectomy is the most preferred treatment modality for localized prostate cancer. Individual decision making is necessary for each patient because of the diversities in the biological characteristics of the prostate cancer. The prediction of pathologic stage, prognosis and cancer specific mortality after curative therapy and quality of life issues are essential for counseling and tailoring treatment in possible candidates of radical prostatectomy. Several studies demonstrated that nomograms are the best predictive tools regarding the other prediction models. For better understanding the nomograms in radical prostatectomy patients, they should be classified according to categories for their use. PSA, Gleason grade and clinical stage are seemed to be the most important prognostic factors in patients who are candidates for radical prostatectomy. Additionally, the pathological parameters are remarkable prognostic criteria. The Partin tables for predicting the radical prostatectomy pathology and Kattan nomograms for predicting the biochemical recurrences free survival rates are the most frequently used nomograms. Today, these nomograms should not replace the clinical decisions but they give significant information for the patients’ prognosis, treatment selection and follow up.

Keywords

Nomogram, Prediction, Prostate Cancer, Prognosis, Radical Prostatectomy

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	P. Boyle and J. Ferlay, “Cancer Incidence and Mortality in Europe, 2004,” Annals of Oncology, Vol. 16, No. 3, 2005, pp. 481-488. doi:10.1093/annonc/mdi098
[2]	S. F. Shariat, P. I. Karakiewicz, V. Margulis and M. W. Kattan, “Inventory of Prostate Cancer Predictive Tools,” Current Opinion in Urology, Vol. 18, 2008, No. 3, pp. 279-296. doi:10.1097/MOU.0b013e3282f9b3e5
[3]	A. W. Partin, J. Yoo, H. B. Carter, J. D. Pearson, D. W. Chan, J. I. Epstein and P. C. Walsh, “The Use of Prostate Specific Antigen, Clinical Stage and Gleason Score to Predict Pathological Stage in Men with Localized Prostate Cancer,” Journal of Urology, Vol. 150, 1993, pp. 110-114.
[4]	M. W. Kattan, J. A. Eastham, A. M. Stapleton, T. M. Wheeler and P. T. Scardino, “A Preoperative Nomogram for Disease Recurrence Following Radical Prostatectomy for Prostate Cancer,” Journal of the National Cancer Institute, Vol. 90, No. 10, 1998, pp. 766-771. doi:10.1093/jnci/90.10.766
[5]	M. W. Kattan, T. M. Wheeler and P. T. Scardino, “Postoperative Nomogram for Disease Recurrence after Radical Prostatectomy for Prostate Cancer,” Journal of Clinical Oncology, Vol. 17, No. 5, 1999, pp. 1499-1507.
[6]	P. B. Snow, D. S. Smith and W. J. Catalona, “Artificial Neural Networks in the Diagnosis and Prognosis of Prostate Cancer: A Pilot Study,” Journal of Urology, Vol. 152, 1994, pp. 1923-1926.
[7]	A. V. D’Amico, R. Whittington, S. B. Malkowicz, D. Schultz, M. Schnall, J. E. Tomaszewski and A. Wein, “A Multivariate Analysis of Clinical and Pathological Factors That Predict for Prostate Specific Antigen Failure after Radical Prostatectomy for Prostate Cancer,” Journal of Urology, Vol. 154, No. 1, 1995, pp. 131-138.
[8]	M. Graefen, A. Haese, U. Pichlmeier, P. G. Hammerer, J. Noldus, K. Butz, A. Erbersdobler, R. P. Henke, U. Michl, S. Fernandez and H. Huland, “A Validated Strategy for Side Specific Prediction of Organ Confined Prostate Cancer: A Tool to Select for Nerve Sparing Radical Prostatectomy,” Journal of Urology, Vol. 165, No. 3, 2001, pp. 857-863. doi:10.1016/S0022-5347(05)66544-5
[9]	F. K. Chun, P. I. Karakiewicz, A. Briganti, J. Walz, M. W. Kattan, H. Huland and M. Graefen, “A Critical Appraisal of Logistic Regression-Based Nomograms, Artificial Neural Networks, Classification and Regression-Tree Models, Look-Up Tables and Risk-Group Stratification Models for Prostate Cancer,” British Journal of Urology International, Vol. 99, No. 4, 2007, pp. 794-800. doi:10.1111/j.1464-410X.2006.06694.x
[10]	M. W. Kattan, “Comparison of Cox Regression with Other Methods for Determining Prediction Models and Nomograms,” Journal of Urology, Vol. 170, No. 6, 2003, pp. S6-S9. doi:10.1097/01.ju.0000094764.56269.2d
[11]	J. E. Oesterling, C. B. Brendler, J. I. Epstein, A. W. Kimball Jr. and P. C. Walsh, “Correlation of Clinical Stage, Serum Prostatic Acid Phosphatase and Preoperative Gleason Grade with Final Pathological Stage in 275 Patients with Clinically Localized Adenocarcinoma of the Prostate,” Journal of Urology, Vol. 138, No. 1, 1987, pp. 92-98.
[12]	P. Narayan, V. Gajendran, S. P. Taylor, A. Tewari, J. C. Presti Jr., R. Leidich, R. Lo, K. Palmer, K. Shinohara and J. T. Spaulding, “The Role of Transrectal Ultrasound-Guided Biopsy-Based Staging, Preoperative Serum Prostate-Specific Antigen, and Biopsy Gleason Score in Prediction of Final Pathologic Diagnosis in Prostate Cancer,” Urology, Vol. 46, No. 2, 1995, pp. 205-212. doi:10.1016/S0090-4295(99)80195-2
[13]	D. V. Makarov, B. J. Trock, E. B. Humphreys, L. A. Mangold, P. C. Walsh, J. I. Epstein and A. W. Partin, “Updated Nomogram to Predict Pathologic Stage of Prostate Cancer Given Prostate-Specific Antigen Level, Clinical Stage, and Biopsy Gleason Score (Partin Tables) Based on Cases from 2000 to 2005,” Urology, Vol. 69, No. 6, 2007, pp. 1095-1101. doi:10.1016/j.urology.2007.03.042
[14]	A. W. Partin, M. W. Kattan, E. N. Subong, P. C. Walsh, K. J. Wojno, J. E. Oesterling, P. T. Scardino and J. D. Pearson, “Combination of Prostate-Specific Antigen, Clinical Stage, and Gleason Score to Predict Pathological Stage of Localized Prostate Cancer. A Multi-institutional Update,” Journal of the American Medical Association, Vol. 277, No. 18, 1997, pp. 1445-1451. doi:10.1001/jama.277.18.1445
[15]	A. W. Partin, L. A. Mangold, D. M. Lamm, P. C. Walsh, J. I. Epstein and J. D. Pearson, “Contemporary Update of Prostate Cancer Staging Nomograms (Partin Tables) for the New Millennium,” Urology, Vol. 58, No. 6, 2001, pp. 843-848. doi:10.1016/S0090-4295(01)01441-8
[16]	M. L. Blute, E. J. Bergstralh, A. W. Partin, P. C. Walsh, M. W. Kattan, P. T. Scardino, J. E. Montie, J. D. Pearson, J. M. Slezak and H. Zincke, “Validation of Partin Tables for Predicting Pathological Stage of Clinically Localized Prostate Cancer,” Journal of Urology, Vol. 164, No. 5, 2000, pp. 1591-1595. do:10.1016/S0022-5347(05)67035-8
[17]	M. Graefen, H. Augustin, P. I. Karakiewicz, P. G. Hammerer, A. Haese, J. Palisaar, J. Blonski, S. Fernandez, A. Erbersdobler and H. Huland, “Can Predictive Models for Prostate Cancer Patients Derived in the United States of America be Utilized in European Patients? A Validation Study of the Partin Tables,” European Urology, Vol. 43, 2003, pp. 6-10. doi:10.1016/S0302-2838(02)00497-9
[18]	H. Augustin, T. Eggert, S. Wenske, P. I. Karakiewicz, J. Palisaar, F. Daghofer, H. Huland and M. Graefen, “Comparison of Accuracy between the Partin Tables of 1997 and 2001 to Predict Final Pathological Stage in Clinically Localized Prostate Cancer,” Journal of Urology, Vol. 171, No. 1, 2004, pp. 177-181. doi:10.1097/01.ju.0000099827.77355.a7
[19]	J. B. Yu, D. V. Makarov, R. Sharma, R. E. Peschel, A. W. Partin and C. P. Gross, “Validation of the Partin Nomogram for Prostate Cancer in a National Sample,” Journal of Urology, Vol. 183, No. 1, 2010, pp. 105-111. doi:10.1016/j.juro.2009.08.143
[20]	R. A. Badalament, M. C. Miller, P. A. Peller, D. C. Young, D. K. Bahn, P. Kochie, G. J. O'Dowd and R. W. Veltri, “An Algorithm for Predicting Nonorgan Confined Prostate Cancer Using the Results Obtained from Sextant Core Biopsies with Prostate Specific Antigen Level,” Journal of Urology, Vol. 156, No. 4, 1996, pp. 1375- 1380. doi:10.1016/S0022-5347(01)65590-3
[21]	M. Ohori, M. W. Kattan, H. Koh, N. Maru, K. M. Slawin, S. Shariat, M. Muramoto, V. E. Reuter, T. M. Wheeler, and P. T. Scardino, “Predicting the Presence and Side of Extracapsular Extension: A Nomogram for Staging Prostate Cancer,” Journal of Urology, Vol. 171, No. 5, 2004, pp. 1844-1849.
[22]	T. Steuber, M. Graefen, A. Haese, A. Erbersdobler, F. K. Chun, T. Schlom, P. Perrotte, H. Huland and P. I. Karakiewicz, “Validation of a Nomogram for Prediction of Side Specific Extracapsular Extension at Radical Prostatectomy,” Journal of Urology, Vol. 175, No. 3, 2006, pp. 939-944. doi:10.1016/S0022-5347(05)00342-3
[23]	N. Satake, M. Ohori, C. Yu, M. W. Kattan, Y. Ohno, A. Miyakawa, T. Hatano and M. Tachibana, “Development and Internal Validation of a Nomogram Predicting Extracapsular Extension in Radical Prostatectomy Specimens,” International Journal of Urology, Vol. 17, No. 3, 2010, pp. 267-272. doi:10.1111/j.1442-2042.2010.02452.x
[24]	H. Koh, M. W. Kattan, P. T. Scardino, K. Suyama, N. Maru, K. Slawin, T. M. Wheeler and M. Ohori, “A Nomogram to Predict Seminal Vesicle Invasion by the Extent and Location of Cancer in Systematic Biopsy Results,” Journal of Urology, Vol. 170, No. 4, 2003, pp. 1203-1208. doi:10.1097/01.ju.0000085074.62960.7b
[25]	A. Baccala Jr., A. M. Reuther, F. J. Bianco Jr., P. T. Scardino, M. W. Kattan and E. A. Klein, “Complete Resection of Seminal Vesicles at Radical Prostatectomy Results in Substantial Long-Term Disease-Free Survival: Multi-Institutional Study of 6740 Patients,” Urology, Vol. 69, No. 3, 2007, pp. 536-540. doi:10.1016/j.urology.2006.12.013
[26]	A. Gallina, F. K. Chun, A. Briganti, S. F. Shariat, F. Montorsi, A. Salonia, A. Erbersdobler, P. Rigatti, L. Valiquette, H. Huland, M. Graefen and P. I. Karakiewicz, “Development and Split-Sample Validation of a Nomogram Predicting the Probability of Seminal Vesicle Invasion at Radical Prostatectomy,” European Urology, Vol. 52, No. 1, 2007, pp. 98-105. doi:10.1016/j.eururo.2007.01.060
[27]	M. Ohori, M. W. Kattan, C. Yu, K. Matsumoto, T. Satoh, J. Ishii, A. Miyakawa, A. Irie, M. Iwamura and M. Tachibana, “Nomogram to Predict Seminal Vesicle Invasion Using the Status of Cancer at the Base of the Prostate on Systematic Biopsy,” International Journal of Urology, Vol. 17, No. 6, 2010, pp. 534-540. doi:10.1111/j.1442-2042.2010.02513.x
[28]	I. Cagiannos, P. Karakiewicz, J. A. Eastham, M. Ohori, F. Rabbani, C. Gerigk, V. Reuter, M. Graefen, P. G. Hammerer, A. Erbersdobler, H. Huland, P. Kupelian, E. Klein, D. I. Quinn, S. M. Henshall, J. J. Grygiel, R. L. Sutherland, P. D. Stricker, C. G. Morash, P. T. Scardino and M. W. Kattan, “A Preoperative Nomogram Identifying Decreased Risk of Positive Pelvic Lymph Nodes in Patients with Prostate Cancer,” Journal of Urology, Vol. 170, No. 5, 2003, pp. 1798-1803. doi:10.1097/01.ju.0000091805.98960.13
[29]	A. Briganti, F. K. Chun, A. Salonia, A. Gallina, E. Farina, L. F. Da Pozzo, P. Rigatti, F. Montorsi and P. I. Karakiewicz, “Validation of a Nomogram Predicting the Probability of Lymph Node Invasion Based on the Extent of Pelvic Lymphadenectomy in Patients with Clinically Localized Prostate Cancer,” British Journal of Urology International, Vol. 98, No. 4, 2006, pp. 788-793. doi:10.1111/j.1464-410X.2006.06318.x
[30]	Y. D. Choi, H. S. Yu, K. H. Choi, et al., “Development of Preoperative Nomogram for Predicting Pelvic Lymph Node Invasion in Patients Undergoing Radical Prostatectomy,” European Urology, Vol. 9, 2010, p. 590.
[31]	F. K. Chun, T. Steuber, A. Erbersdobler, E. Currlin, J. Walz, T. Schlomm, A. Haese, H. Heinzer, M. McCormack, H. Huland, M. Graefen and P. I. Karakiewicz, “Development and Internal Validation of a Nomogram Predicting the Probability of Prostate Cancer Gleason Sum Upgrading between Biopsy and Radical Prostatectomy Pathology,” European Urology, Vol. 49, No. 5, 2006, pp. 820-826. doi:10.1016/j.eururo.2005.11.007
[32]	F. K. Chun, A. Briganti, S. F. Shariat, M. Graefen, F. Montorsi, A. Erbersdobler, T. Steuber, A. Salonia, E. Currlin, V. Scattoni, M. G. Friedrich, T. Schlomm, A. Haese, U. Michl, R. Colombo, H. Heinzer, L. Valiquette, P. Rigatti, C. G. Roehrborn, H. Huland and P. I. Karakiewicz, “Significant Upgrading Affects a Third of Men Diagnosed with Prostate Cancer: Predictive Nomogram and Internal Validation,” British Journal of Urology International, Vol. 98, No. 2, 2006, pp. 329-334. doi:10.1111/j.1464-410X.200
[33]	D. A. Stackhouse, L. Sun, F. R. Schroeck, J. Jayachandran, A. A. Caire, C. O. Acholo, C. N. Robertson, D. M. Albala, T. J. Polascik, C. F. Donatucci, K. E. Maloney and J. W. Moul, “Factors Predicting Prostatic Biopsy Gleason Sum under Grading,” Journal of Urology, Vol. 182, 2009, pp. 118-122. doi:10.1016/j.juro.2009.02.127
[34]	T. Steuber, F. K. Chun, A. Erbersdobler, A. Briganti, A. Haese, M. Graefen, T. Schlomm, L. Valiquette, H. Huland and P. I. Karakiewicz, “Development and Internal Validation of Preoperative Transition Zone Prostate Cancer Nomogram,” Urology, Vol. 68, No. 6, 2006, pp. 1295-1300. doi:10.1016/j.urology.2006.08.1066
[35]	P. A. Peller, D. C. Young, D. P. Marmaduke, W. L. Marsh and R. A. Badalament, “Sextant Prostate Biopsies. A Histopathologic Correlation with Radical Prostatectomy Specimens,” Cancer, Vol. 75, No. 2, 1995, pp. 530- 538. doi:10.1002/1097-0142(19950115)75:2<530::AID-CNCR2820750216>3.0.CO;2-Y
[36]	M. W. Kattan, J. A. Eastham, T. M. Wheeler, N. Maru, P. T. Scardino, A. Erbersdobler, M. Graefen, H. Huland, H. Koh, S. F. Shariat, K. M. Slawin and M. Ohori, “Counseling Men with Prostate Cancer: A Nomogram for Predicting the Presence of Small, Moderately Differentiated, Confined Tumors,” Journal of Urology, Vol. 170, No. 5, 2003, pp. 1792-1797. doi:10.1097/01.ju.0000091806.70171.41
[37]	S. Y. Eskicorapci, E. Karabulut, L. Turkeri, S. Baltaci, C. Cal, G. Toktas, H. Akpinar, G. Ozer, S. Sozen, R. Tokuc, M. Lekili, A. Soylu, S. Albayrak, H. Sahin, R. Alpar and H. Ozen, “Validation of 2001 Partin Tables in Turkey: A Multicenter Study,” European Urology, Vol. 47, No. 2, 2005, pp. 185-189. doi:10.1016/j.eururo.2004.08.002
[38]	D. G. Bostwick, J. Qian, E. Bergstralh, P. Dundore, J. Dugan, R. P. Myers and J. E. Oesterling, “Prediction of Capsular Perforation and Seminal Vesicle Invasion in Prostate Cancer,” Journal of Urology, Vol. 155, No. 4, 1996, pp. 1361-1367. doi:10.1016/S0022-5347(01)66267-0
[39]	D. A. Ackerman, J. M. Barry, R. A. Wicklund, N. Olson and B. A. Lowe, “Analysis of Risk Factors Associated with Prostate Cancer Extension to the Surgical Margin and Pelvic Node Metastasis at Radical Prostatectomy,” Journal of Urology, Vol. 150, No. 6, 1993, pp. 1845-1850.
[40]	F. Rabbani, A. Bastar and W. R. Fair, “Site Specific Predictors of Positive Margins at Radical Prostatectomy: An Argument for Risk Based Modification of Technique,” Journal of Urology, Vol. 160, No. 5, 1998, pp. 1727- 1733. doi:10.1016/S0022-5347(01)62394-2
[41]	U. Capitanio, P. I. Karakiewicz, C. Jeldres, A. Briganti, A. Gallina, N. Suardi, A. Cestari, G. Guazzoni, A. Salonia and F. Montorsi, “The Probability of Gleason Score Upgrading between Biopsy and Radical Prostatectomy Can Be Accurately Predicted,” International Journal of Urology, Vol. 16, No. 5, 2009, pp. 526-529. doi:10.1111/j.1442-2042.2009.02270.x
[42]	M. W. Kattan, S. F. Shariat, B. Andrews, K. Zhu, E. Canto, K. Matsumoto, M. Muramoto, P. T. Scardino, M. Ohori, T. M. Wheeler and K. M. Slawin, “The Addition of Interleukin-6 Soluble Receptor and Transforming Growth Factor Beta1 Improves a Preoperative Nomogram for Predicting Biochemical Progression in Patients with Clinically Localized Prostate Cancer,” Journal of Clinical Oncology, Vol. 21, No. 19, 2003, pp. 3573-3579. doi:10.1200/JCO.2003.12.037
[43]	A. J. Stephenson, P. T. Scardino, J. A. Eastham, F. J. Bianco Jr., Z. A. Dotan, P. A. Fearn and M. W. Kattan, “Preoperative Nomogram Predicting the 10-Year Probability of Prostate Cancer Recurrence after Radical Prostatectomy,” Journal of the National Cancer Institute, Vol. 98, No. 10, 2006, pp. 715-717. doi:10.1093/jnci/djj190
[44]	S. Y. Eskicorapci, L. Turkeri, E. Karabulut, C. Cal, H. Akpinar, S. Baltaci, K. Baykal, M. W. Kattan and H. Ozen, “Validation of Two Preoperative Kattan Nomograms Predicting Recurrence after Radical Prostatectomy for Localized Prostate Cancer in Turkey: A Multicenter Study of the Uro-Oncology Society,” Urology, Vol. 74, No. 6, 2009, pp. 1289-1295. doi:10.1016/j.urology.2009.03.019
[45]	A. V. D'Amico, “Combined-Modality Staging for Localized Adenocarcinoma of the Prostate,” Oncology (Williston Park), Vol. 15, No. 8, 2001, pp. 1049-1059.
[46]	M. Graefen, P. I. Karakiewicz, I. Cagiannos, et al., “Validation Study of the Accuracy of a Postoperative Nomogram for Recurrence after Radical Prostatectomy for Localized Prostate Cancer,” Journal of Clinical Oncology, Vol. 20, No. 20, 2002, pp. 951-956. doi:10.1200/JCO.20.4.951
[47]	A. J. Stephenson, P. T. Scardino, J. A. Eastham, et al., “Postoperative Nomogram Predicting the 10-Year Probability of Prostate Cancer Recurrence after Radical Prostatectomy,” Journal of Clinical Oncology, Vol. 23, No. 28, 2005, pp. 7005-7012. doi:10.1200/JCO.2005.01.867
[48]	J. W. Moul, R. R. Connelly, D. P. Lubeck, J. J. Bauer, L. Sun, S. C. Flanders, G. D. Grossfeld and P. R. Carroll, “Predicting Risk of Prostate Specific Antigen Recurrence after Radical Prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor Databases,” Journal of Urology, Vol. 166, No. 4, 2001, pp. 1322-1327. doi;10.1016/S0022-5347(05)65761-8
[49]	J. J. Bauer, R. R. Connelly, I. A. Seterhenn, J. Deausen, S. Srivastava, D. G. McLeod and J. W. Moul, “Biostatistical Modeling Using Traditional Preoperative and Pathological Prognostic Variables in the Selection of Men at High Risk for Disease Recurrence after Radical Prostatectomy for Prostate Cancer,” Journal of Urology, Vol. 159, No. 3, 1998, pp. 929-933. doi:10.1016/S0022-5347(01)63773-X
[50]	M. L. Blute, E. J. Bergstralh, A. Iocca, B. Scherer and H. Zincke, “Use of Gleason Score, Prostate Specific Antigen, Seminal Vesicle and Margin Status to Predict Biochemical Failure after Radical Prostatectomy,” Journal of Urology, Vol. 165, No. 1, 2001, pp. 119-125. doi:10.1097/00005392-200101000-00030
[51]	A. V. D’Amico, R. Whittington, S. B. Malkowicz, J. Fondurulia, M. H. Chen, J. E. Tomaszewski and A. Wein, “The Combination of Preoperative Prostate Specific Antigen and Postoperative Pathological Findings to Predict Prostate Specific Antigen Outcome in Clinically Localized Prostate Cancer,” Journal of Urology, Vol. 160, No. 6, 1998, pp. 2096-2101.
[52]	M. Han, A. W. Partin, M. Zahurak, S. Piantadosi, J. I. Epstein and P. C. Walsh, “Biochemical (Prostate Specific Antigen) Recurrence Probability Following Radical Prostatectomy for Clinically Localized Prostate Cancer,” Journal of Urology, Vol. 169, No. 2, 2003, pp. 517-523. doi:10.1016/S0022-5347(05)63946-8
[53]	D. M. Moreira, J. C. Presti Jr., W. J. Aronson, M. K. Terris, C. J. Kane, C. L. Amling, L. L. Sun, J. W. Moul and S. J. Freedland, “The Effect of Race on the Discriminatory Accuracy of Models to Predict Biochemical Recurrence after Radical Prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center Databases,” Prostate Cancer and Prostatic Diseases, Vol. 13, No. 1, 2010, pp. 87-93. doi:10.1038/pcan.2009.48
[54]	R. Thanigasalam, K. K. Rasiah, P. D. Stricker, A. M. Haynes, S. I. Sutherland, R. L. Sutherland, S. M. Henshall and L. G. Horvath, “Stage Migration in Localized Prostate Cancer Has No Effect on the Post-Radical Prostatectomy Kattan Nomogram,” British Journal of Urology International, Vol. 105, No. 5, 2010, pp. 642-647. doi:10.1111/j.1464-410X.2009.08842.x
[55]	J. Walz, F. K. Chun, E. A. Klein, A. Reuther, F. Saad, M. Graefen, H. Huland and P. I. Karakiewicz, “Nomogram Predicting the Probability of Early Recurrence after Radical Prostatectomy for Prostate Cancer,” Journal of Urology, Vol. 181, No. 2, 2009, pp. 601-608. doi:10.1016/j.juro.2008.10.033
[56]	F. R. Schroeck, W. J. Aronson, J. C. Presti Jr., M. K. Terris, C. J. Kane, C. L. Amling and S. J. Freedland, “Do Nomograms Predict Aggressive Recurrence after Radical Prostatectomy More Accurately than Biochemical Recurrence Alone?” British Journal of Urology International, Vol. 103, No. 5, 2009, pp. 603-608. doi:10.1111/j.1464-410X.2008.08118.x
[57]	F. R. Schroeck, M. W. Kattan, J. W. Moul, W. J. Aronson, J. C. Presti Jr., M. K. Terris, C. J. Kane, C. L. Amling, L. Sun and S. J. Freedland, “Re-calibration and External Validation of an Existing Nomogram to Predict Aggressive Recurrences after Radical Prostatectomy,” British Journal of Urology International, Vol. 105, No. 12, 2010, pp. 1654-1659. doi:10.1111/j.1464-410X.2009.09060.x
[58]	A. J. Stephenson, M. W. Kattan, J. A. Eastham, F. J. Bianco Jr., O. Yossepowitch, A. J. Vickers, E. A. Klein, D. P. Wood and P. T. Scardino, “Prostate Cancer-Specific Mortality after Radical Prostatectomy for Patients Treated in the Prostate-Specific Antigen Era,” Journal of Clinical Oncology, Vol. 27, No. 26, 2009, pp. 4300-4305. doi:10.1200/JCO.2008.18.2501
[59]	C. R. Porter, N. Suardi, U. Capitanio, G. C. Hutterer, K. Kodama, R. P. Gibbons, R. Correa Jr., P. Perrotte, F. Montorsi and P. I. Karakiewicz, “A Nomogram Predicting Prostate Cancer-Specific Mortality after Radical Prostatectomy,” Urologia Internationalis, Vol. 84, No. 2, 2010, pp. 132-140. doi:10.1159/000277588
[60]	M. R. Cooperberg, D. J. Pasta, E. P. Elkin, M. S. Litwin, D. M. Latini, J. Du Chane and P. R. Carroll, “The University of California, San Francisco Cancer of the Prostate Risk Assessment Score: A Straightforward and Reliable Preoperative Predictor of Disease Recurrence after Radical Prostatectomy,” Journal of Urology, Vol. 173, No. 6, 2005, pp. 1938-1942. doi:10.1097/01.ju.0000158155.33890.e7
[61]	M. Graefen, J. Noldus, U. Pichlmeier, A. Haese, P. Hammerer, S. Fernandez, S. Conrad, R. Henke, E. Huland and H. Huland, “Early Prostate-Specific Antigen Relapse after Radical Retropubic Prostatectomy: Prediction on the Basis of Preoperative and Postoperative Tumor Characteristics,” European Urology, Vol. 36, No. 1, 1999, pp. 21-30. doi:10.1159/000019922
[62]	S. J. McAleer, D. Schultz, R. Whittington, S. B. Malkowicz, A. Renshaw, A. Wein, J. P. Richie and A. V. D’Amico, “PSA Outcome Following Radical Prostatectomy for Patients with Localized Prostate Cancer Stratified by Prostatectomy Findings and the Preoperative PSA Level,” Urologic Oncology, Vol. 23, No. 5, 2005, pp. 311-317. doi:10.1016/j.urolonc.2004.12.013
[63]	A. J. Stephenson, D. P. Wood, M. W. Kattan, E. A. Klein, P. T. Scardino, J. A. Eastham and B. S. Carver, “Location, Extent and Number of Positive Surgical Margins Do Not Improve Accuracy of Predicting Prostate Cancer Recurrence after Radical Prostatectomy,” Journal of Urology, Vol. 182, No. 4, 2009, pp. 1357-1363. doi:10.1016/j.juro.2009.06.046
[64]	J. C. Hu, E. P. Elkin, D. J. Pasta, D. P. Lubeck, M. W. Kattan, P. R. Carroll and M. S. Litwin, “Predicting Quality of Life after Radical Prostatectomy: Results from CaPSURE,” Journal of Urology, Vol. 171, No. 2, 2004, pp. 703-708. doi:10.1097/01.ju.0000107964.61300.f6
[65]	P. C. Albertsen, J. A. Hanley, D. F. Gleason and M. J. Barry, “Competing Risk Analysis of Men Aged 55 to 74 Years at Diagnosis Managed Conservatively for Clinically Localized Prostate Cancer,” Journal of the American Medical Association, Vol. 280, No. 11, 1998, pp. 975-980. doi:10.1001/jama.280.11.975
[66]	M. W. Kattan, D. Giri, K. S. Panageas, A. Hummer, M. Cranor, K. J. Van Zee, C. A. Hudis, L. Norton, P. I. Borgen and L. K. Tan, “A Tool for Predicting Breast Carcinoma Mortality in Women Who Do Not Receive Adjuvant Therapy,” Cancer, Vol. 101, No. 11, 2004, pp. 2509- 2515. doi;10.1002/cncr.20635
[67]	L. Wang, H. Hricak, M. W. Kattan, H. N. Chen, K. Kuroiwa, H. F. Eisenberg and P. T. Scardino, “Prediction of Seminal Vesicle Invasion in Prostate Cancer: Incremental Value of Adding Endorectal MR Imaging to the Kattan Nomogram,” Radiology, Vol. 242, No. 1, 2007, pp. 182-188. doi:10.1148/radiol.2421051254